Table 2. Evolution of seroprevalence and disease prevalence in the Boffa HAT focus.
| Boffa West (no vector control) | Boffa East (vector control) | |||||
|---|---|---|---|---|---|---|
| 2012 | 2013 | P 4 | 2012 | 2013 | P 4 | |
| Number tested | 3344 | 2885 | 7927 | 6564 | ||
| CATT 1 positive | 103 (3.08%) | 68 (2.36%) | 0.08 | 134 (1.69%) | 87 (1.32%) | 0.07 |
| Specific serology (CATT+/TL+) 2 | 31 (0.93%) | 26 (0.9%) | 0.92 | 34 (0.43%) | 13 (0.2%) | 0.01 |
| Confirmed HAT 3 | 18 (0.54%) | 21 (0.73%) | 0.34 | 24 (0.30%) | 7 (0.11%) | 0.01 |
| Unconfirmed with specific serology | 13 (0.39%) | 5 (0.17%) | 0.11 | 10 (0.13%) | 6 (0.09%) | 0.53 |
Prevalence data (in brackets) were calculated according to the total population tested in each of the two areas in 2012 and 2013. Former HAT patients who were diagnosed and treated prior to the 2012 survey (14 and 11 in Boffa West and Boffa East respectively) and to the 2013 survey (26 and 28 in Boffa West and Boffa East respectively) were removed from this analysis.
1 Card Agglutination Test for Trypanosomiasis
2 Individuals that were both positive to the CATT and the T. b. gambiense immune trypanolysis test were considered to harbour a specific serology to T. b. gambiense.
3 Trypanosomes were detected by direct microscopic examination of lymph node aspirates or by the mini-anion exchange centrifugation test performed on buffy coat.
4 Pearson’s Chi-squared test P-value (2012–2013 comparison).